U.S. flag

An official website of the United States government

NM_001042492.3(NF1):c.7158dup (p.Asn2387Ter) AND Neurofibromatosis, type 1

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Mar 31, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001943811.4

Allele description [Variation Report for NM_001042492.3(NF1):c.7158dup (p.Asn2387Ter)]

NM_001042492.3(NF1):c.7158dup (p.Asn2387Ter)

Gene:
NF1:neurofibromin 1 [Gene - OMIM - HGNC]
Variant type:
Duplication
Cytogenetic location:
17q11.2
Genomic location:
Preferred name:
NM_001042492.3(NF1):c.7158dup (p.Asn2387Ter)
HGVS:
  • NC_000017.11:g.31343104dup
  • NG_009018.1:g.253128dup
  • NM_000267.3:c.7095dup
  • NM_001042492.3:c.7158dupMANE SELECT
  • NP_000258.1:p.Asn2366Ter
  • NP_001035957.1:p.Asn2387Ter
  • LRG_214t1:c.7095dup
  • LRG_214:g.253128dup
  • LRG_214p1:p.Asn2366Ter
  • NC_000017.10:g.29670119_29670120insT
  • NC_000017.10:g.29670122dup
Protein change:
N2366*
Links:
dbSNP: rs1597851420
NCBI 1000 Genomes Browser:
rs1597851420
Molecular consequence:
  • NM_000267.3:c.7095dup - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001042492.3:c.7158dup - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Name:
Neurofibromatosis, type 1 (NF1)
Synonyms:
NEUROFIBROMATOSIS, TYPE I; Recklinghausen's disease; Von Recklinghausen disease; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0018975; MedGen: C0027831; Orphanet: 636; OMIM: 162200

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV002196224Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Mar 31, 2022)
germlineclinical testing

PubMed (5)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations.

Pros E, Gómez C, Martín T, Fábregas P, Serra E, Lázaro C.

Hum Mutat. 2008 Sep;29(9):E173-93. doi: 10.1002/humu.20826.

PubMed [citation]
PMID:
18546366

LOVD v.2.0: the next generation in gene variant databases.

Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den Dunnen JT.

Hum Mutat. 2011 May;32(5):557-63. doi: 10.1002/humu.21438. Epub 2011 Feb 22.

PubMed [citation]
PMID:
21520333
See all PubMed Citations (5)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV002196224.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (5)

Description

For these reasons, this variant has been classified as Pathogenic. This premature translational stop signal has been observed in individual(s) with neurofibromatosis, type 1 (PMID: 18546366, 21520333). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Asn2366*) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024